- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
Patent holdings for IPC class A61K 31/536
Total number of patents in this class: 503
10-year publication summary
|
32
|
29
|
35
|
29
|
32
|
34
|
24
|
31
|
36
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4567 |
12 |
| ChemoCentryx, Inc. | 371 |
11 |
| F. Hoffmann-La Roche AG | 7847 |
8 |
| The Regents of the University of California | 20502 |
8 |
| Merck Sharp & Dohme LLC | 3719 |
8 |
| The University of Liverpool | 308 |
7 |
| GABA Therapeutics Inc. | 7 |
7 |
| Actelion Pharmaceuticals Ltd | 508 |
6 |
| Emory University | 1693 |
6 |
| ViiV Healthcare Company | 164 |
6 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 338 |
6 |
| Shanghai Apeiron Therapeutics Company Limited | 36 |
6 |
| Novartis AG | 10420 |
5 |
| Bristol-myers Squibb Company | 4821 |
5 |
| AstraZeneca AB | 2832 |
5 |
| Bayer Pharma AG | 1031 |
5 |
| Amgen Inc. | 4335 |
5 |
| Cipla Limited | 469 |
5 |
| Cornell University | 3386 |
5 |
| Kyowa Hakko Kirin Co., Ltd. | 279 |
5 |
| Other owners | 372 |